Unicycive Therapeutics (NASDAQ:UNCY) said the U.S. Food and Drug Administration issued a Complete Response Letter for its resubmitted new drug application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis.
Patrick Industries (NASDAQ:PATK) and LCI Industries (NYSE:LCII) have entered into a definitive agreement to combine in an all-stock merger.
GreenTree Hospitality (NYSE:GHG) reported first quarter 2026 total revenues of RMB227.7 million, equivalent to US$33 million, a decrease of 14% year over year.
AC Immune (NASDAQ:ACIU) reported 12-month interim data from the Phase 1b/2 ABATE trial of ACI-24 in 74 patients with prodromal Alzheimer’s disease across cohorts AD1-AD3.
HeartBeam (NASDAQ:BEAT) announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection.
Pasithea Therapeutics (NASDAQ:KTTA) reported positive interim Phase 1 clinical trial results for PAS-004, an oral MEK inhibitor being tested in advanced MAPK pathway-driven solid tumors, including patients previously treated with MEK and BRAF inhibitors.
Novocure (NASDAQ:NVCR) said its Optune Pax device has received CE Mark approval for treating adult patients with locally advanced pancreatic cancer of exocrine origin in combination with gemcitabine and nab-paclitaxel.
Redwire (NYSE:RDW) announced it has been awarded a contract by Taiwan Color Optics, a subsidiary of SemiLux International, to deliver its Penguin Mk2.5 VTOL uncrewed aerial system to the Taiwan Coast Guard.
XRP (CRYPTO:XRP) was trading at US$1.05, down 6% on the week and remaining below key resistance levels.
Webull (NASDAQ:BULL), through its subsidiary Webull Thailand, signed an agreement to acquire Pi Securities, a Thai investment services firm with more than 50 years of market experience.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
